Where does Bergenbio ASA rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Bergenbio ASA ranks #17,488 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Bergenbio ASA hold?

Bergenbio ASA holds 16 US utility patents granted between 2017 and 2023, spanning 10 technology areas.

What is Bergenbio ASA's Innovation Score?

Bergenbio ASA has an Innovation Score of 34.8 out of 100 (49th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Bergenbio ASA focus on?

Bergenbio ASA's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 12 patents, ranking #1,593 of 6,058 assignees active in that subclass. Grants appear in 10 CPC subclasses total.

Is Bergenbio ASA's patent grant rate increasing or decreasing?

Bergenbio ASA's recent grant velocity is +0% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Bergenbio ASA's patents?

Bergenbio ASA's patents average 18.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Bergenbio ASA patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Bergenbio ASA

USPTO PatentsView assignee record - 16 granted patents across 10 technology areas, recorded in grant years 2017–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Bergenbio ranks #17,488 of 49,997 tracked US assignees by granted-patent volume, with 16 patents across 10 technology areas.

#17,488
of 49,997 US assignees by volume: 49th percentile
by Innovation Score (34.8/100): 18.9
avg claims per patent: +0%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R17488 · Foreign Corporation #17,488 · 16 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-FLAT · BOOK-FULL

GRANTS-MICRO 16 grants
MID-PACK #17,488/49,997
PHOTO-FINISH BAROnova
CPC-FOCUS A61P · 10 areas
INNOV-THIN 34.8/100
CLAIMS-RICH 18.9 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-FLAT +0% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: BAROnova, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Bergenbio’s 34.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.8 pts (28%) Velocity 2.5 pts (7%) Breadth 11.2 pts (32%) Claim depth 11.4 pts (33%)

Qualcomm Incorporated · highest

85
Bergenbio ASA · this assignee

35
3D Lighting… · lowest

7

What this shows Bergenbio's Innovation Score is 34.8/100 (49th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Bergenbio?

Each dot is one of Bergenbio’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Bergenbio’s own 18.9 claims/patent is ABOVE the 13.1 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Bergenbio vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Bergenbio's grants concentrate

Bergenbio ASA is a focused PatentsView assignee: 10 CPC subclasses with 75% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2021 (4 grants) versus a trough of 1 in 2020. By volume, Bergenbio sits between BAROnova, Inc. and Biomarin Technologies B.V..

Bergenbio's three-year grant acceleration

Bergenbio ASA shows 3 grants in 2022–2024 against only 8 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Baronova

16
Barrday

16
Base Pair Biotech…

16
Beijing Eryiju Te…

16
Bericap Holding

16
Biolog-id

16
Biological Dynami…

16
Biomarin B V

16
Bergenbio ASA ◀

16

What this shows Bergenbio holds 16 patents at rank #17,481, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Bergenbio

By rank, the assignees closest to #17,481 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Bergenbio's primary technology class.

Bergenbio's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

35 49th percentile higher than 49% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Bergenbio ASA patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	2	12.5%
2018	3	18.8%
2019	3	18.8%
2020	1	6.3%
2021	4	25.0%
2022	1	6.3%
2023	2	12.5%

Which technologies does Bergenbio ASA patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 12

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 12

C07K - Peptides 9

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 7

C07D - Heterocyclic Compounds 3

C07C - Acyclic OR Carbocyclic Compounds 2

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 2

Y02A - Technologies FOR Adaptation TO Climate Change 1

C12Y - Enzymes 1

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 1

Top 10 of 10 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Bergenbio ASA's patent record in context - here's where to go next.

Bergenbio ASA's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 75% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #17,488 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Bergenbio ASA against BAROnova, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 34.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.